Opko Health Inc. acquired publicly traded Bio-Reference Laboratories Inc. (BRLI; clinical laboratory services) for $1.4bn in stock--2.75 Opko shares (valued at $49.14, a 48% premium) for each BRLI share. (Jun.)
Through the deal, Opko is now the owner of the third-largest (according to BRLI) US full-service clinical lab, behind Quest Diagnostics and LabCorp. Lab services should further diversify Opko's offerings...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?